Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg), 100 Tablets per carton (10 unit dose blist...

FDA Recall #D-0136-2025 — Class II — November 19, 2024

Recall #D-0136-2025 Date: November 19, 2024 Classification: Class II Status: Ongoing

Product Description

Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 42292-040-20

Reason for Recall

Subpotent and Superpotent Drug

Recalling Firm

Mylan Institutional, Inc. — Rockford, IL

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

205 cartons

Distribution

Nationwide in the USA.

Code Information

Lot #: 3115869, Exp. Date 03/2025

Status

Ongoing

Voluntary / Mandated

Voluntary: Firm initiated

What Should You Do?

Stop using this medication immediately and contact your pharmacist or doctor. Do not flush medications down the drain. Return the product to the place of purchase for a refund or replacement.

Back to All Drug Recalls